PMID- 27843537
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1948-5182 (Print)
IS  - 1948-5182 (Electronic)
VI  - 8
IP  - 30
DP  - 2016 Oct 28
TI  - Retrospective study of the associations between hepatitis C virus infection and 
      metabolic factors.
PG  - 1269-1278
AB  - AIM: To evaluate the bidirectional association between metabolic syndrome (MS) 
      components and antiviral treatment response for chronic hepatitis C virus (HCV) 
      infection. METHODS: This retrospective cohort study included 119 HCV + patients 
      treated with pegylated-interferon-alpha and ribavirin. Metabolic characteristics and 
      laboratory data were collected from medical records. Differences in baseline 
      clinical and demographic risk factors between responders and non-responders were 
      assessed using independent samples t-tests or chi(2) tests. The effects of 
      sustained viral response (SVR) to antiviral treatment on de novo impairments in 
      MS components, including impaired fasting glucose (IFG) and type 2 diabetes 
      mellitus (T2DM), were assessed using univariable and multivariable logistic 
      regression analysis, while the effect of MS components on SVR was assessed using 
      univariable logistic regression analysis. RESULTS: Of the 119 patients, 80 (67%) 
      developed SVR over the average 54 +/- 13 mo follow-up. The cumulative risks for de 
      novo T2DM and IFG were 5.07- (95%CI: 1.261-20.4, P = 0.022) and 3.87-fold higher 
      (95%CI: 1.484-10.15, P = 0.006), respectively for non-responders than responders, 
      when adjusted for the baseline risk factors age, sex, HCV genotype, high viral 
      load, and steatosis. Post-treatment triglyceride levels were significantly lower 
      in non-responders than in responders (OR = 0.27; 95%CI: 0.069-0.962, P = 0.044). 
      Age and HCV genotype 3 were significantly different between responders and 
      non-responders, and MS components were not significantly associated with SVR. 
      Steatosis tended to attenuate SVR (OR = 0.596; 95%CI: 0.331-1.073, P = 0.08). 
      CONCLUSION: SVR was associated with lower de novo T2DM and IFG incidence and 
      higher triglyceride levels. Patients infected with HCV should undergo T2DM 
      screening and antidiabetic treatment.
FAU - Yair-Sabag, Shira
AU  - Yair-Sabag S
AD  - Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, 
      Gastroenterology Institute, Emek Medical Center, Afula 18742, Israel.
FAU - Nussinson, Elchanan
AU  - Nussinson E
AD  - Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, 
      Gastroenterology Institute, Emek Medical Center, Afula 18742, Israel.
FAU - Ben-Assuli, Ofir
AU  - Ben-Assuli O
AD  - Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, 
      Gastroenterology Institute, Emek Medical Center, Afula 18742, Israel.
FAU - Shibli, Fahmi
AU  - Shibli F
AD  - Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, 
      Gastroenterology Institute, Emek Medical Center, Afula 18742, Israel.
FAU - Shahbari, Azmi
AU  - Shahbari A
AD  - Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, 
      Gastroenterology Institute, Emek Medical Center, Afula 18742, Israel.
FAU - Zelber-Sagi, Shira
AU  - Zelber-Sagi S
AD  - Shira Yair-Sabag, Elchanan Nussinson, Fahmi Shibli, Azmi Shahbari, 
      Gastroenterology Institute, Emek Medical Center, Afula 18742, Israel.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Hepatol
JT  - World journal of hepatology
JID - 101532469
PMC - PMC5084056
OTO - NOTNLM
OT  - Antiviral therapy
OT  - Direct acting antiviral agents
OT  - Hepatic steatosis
OT  - Hepatitis C virus
OT  - Metabolic syndrome
OT  - Peg interferon alpha
OT  - Ribavirin
OT  - Sustained viral response
OT  - Type 2 diabetes mellitus
COIS- Conflict-of-interest statement: There are no conflicts of interest to declare.
EDAT- 2016/11/16 06:00
MHDA- 2016/11/16 06:01
PMCR- 2016/10/28
CRDT- 2016/11/16 06:00
PHST- 2016/05/08 00:00 [received]
PHST- 2016/07/28 00:00 [revised]
PHST- 2016/09/13 00:00 [accepted]
PHST- 2016/11/16 06:00 [entrez]
PHST- 2016/11/16 06:00 [pubmed]
PHST- 2016/11/16 06:01 [medline]
PHST- 2016/10/28 00:00 [pmc-release]
AID - 10.4254/wjh.v8.i30.1269 [doi]
PST - ppublish
SO  - World J Hepatol. 2016 Oct 28;8(30):1269-1278. doi: 10.4254/wjh.v8.i30.1269.